|
Pomegranate Juice for PSA-only Prostate Cancer Recurrence
Untitled Document
Name of the Trial
Phase III Randomized Study of Pomegranate Juice in Patients With Rising Prostate-Specific
Antigen Levels After Surgery or Radiotherapy for Localized Prostate Cancer (UCLA-0507059-01).
See the protocol
summary.
Principal Investigators
 |
Dr. Allan Pantuck
Principal Investigator |
Dr. Allan Pantuck and Dr. Arie Belldegrun, Jonsson Comprehensive Cancer Center
at UCLA.
Why This Trial Is Important
Surgery and radiotherapy are common treatments for localized prostate cancer
(cancer confined to the prostate gland). Following such treatments, doctors
may monitor the blood level of a protein called prostate-specific antigen (PSA).
An increase in PSA level may be an early indicator that prostate cancer has
returned. Research has shown that the length of time it takes for a rising PSA
level to double (called PSA doubling time) can be useful in predicting the risk
of prostate cancer progression and death.
Currently, there is no standard treatment for men who have recurrent prostate
cancer detected by an increase in PSA level only. Consequently, doctors want
to develop treatments that can slow down or reverse increases in PSA without
causing serious side effects.
In this trial, researchers are exploring the potential of pomegranate juice
to slow or reverse increasing PSA levels in men who have undergone treatment
for localized prostate cancer. Pomegranate juice is rich in phytochemicals,
substances that have been shown in laboratory studies to inhibit cancer growth
and spread. Men in this trial will be randomly assigned to drink a special preparation
of pomegranate juice or a placebo drink daily for up to one year.
"In a phase II trial we conducted, daily consumption of pomegranate juice
resulted in a significant lengthening of PSA doubling time and disease stabilization,"
said Dr. Pantuck. "We hope to verify those results in a phase III, double-blinded,
placebo-controlled study."
Who Can Join This Trial
Researchers seek to enroll 250 patients aged 18 and over with prostate cancer
that have completed prior surgery, cryotherapy, or radiotherapy but have rising
PSA levels. See the list
of eligibility criteria.
Study Sites and Contact Information
Study sites in the United States are recruiting patients for this trial. See
the list
of study contacts or call 1-800-4-CANCER (1-800-422-6237) for more information.
Back to Top |
